XML 22 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Cumulative-effect adjustment from adoption of ASC 2020-06
Leveraged Stock Units (LSUs)
Class A Common Stock
Class A Common Stock
Performance-Based Restricted Stock Units (PSUs)
Class A Common Stock
Leveraged Stock Units (LSUs)
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative-effect adjustment from adoption of ASC 2020-06
Additional Paid-In Capital
Performance-Based Restricted Stock Units (PSUs)
Additional Paid-In Capital
Leveraged Stock Units (LSUs)
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative-effect adjustment from adoption of ASC 2020-06
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2021 0                          
Series A preferred stock , beginning balance at Dec. 31, 2021 $ 0                          
Series A preferred stock , ending balance (in shares) at Dec. 31, 2022 0                          
Series A preferred stock , ending balance at Dec. 31, 2022 $ 0                          
Beginning balance (in shares) at Dec. 31, 2021       90,759,000                    
Beginning balance at Dec. 31, 2021 693,633 $ (66,383)   $ 908     $ 1,340,989 $ (106,172)     $ (362) $ (626,779) $ 39,789 $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation expense 33,981           33,981              
Exercise of stock options (in shares)       651,000                    
Exercise of stock options 4,452     $ 6     4,446              
Restricted stock units vested, net of shares withheld for taxes (in shares)       496,000                    
Restricted stock units vested, net of shares withheld for taxes (7,086)     $ 5     (7,091)              
Stock units vested, net of shares withheld for taxes (in shares)       459,000                    
Stock units vested, net of shares withheld for taxes (11,232)     $ 5     (11,237)              
Exchange of 2024 notes (in shares)       5,394,000                    
Exchange of 2024 notes 101,857     $ 54     101,803              
Shares issued for acquisition (in shares)       3,742,000                    
Shares issued for acquisition 130,175     $ 37     130,138              
Foreign currency translation adjustment (816)                   (816)      
Net loss attributable to common shareholders of Evolent Health, Inc. (19,164)                     (19,164)    
Ending balance (in shares) at Dec. 31, 2022       101,501,000                    
Ending balance at Dec. 31, 2022 $ 859,417     $ 1,015     1,486,857       (1,178) (606,154)   (21,123)
Increase (Decrease) in Temporary Equity [Roll Forward]                            
Issuance of series A preferred stock, net of issuance costs (in shares) 175,000                          
Issuance of series A preferred stock, net of issuance costs $ 168,000                          
Series A preferred stock , ending balance (in shares) at Dec. 31, 2023 175,000                          
Series A preferred stock , ending balance at Dec. 31, 2023 $ 178,427                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation expense 40,501           40,501              
Exercise of stock options (in shares)       1,406,000                    
Exercise of stock options 12,519     $ 14     12,505              
Restricted stock units vested, net of shares withheld for taxes (in shares)       630,000                    
Restricted stock units vested, net of shares withheld for taxes (11,317)     $ 6     (11,323)              
Stock units vested, net of shares withheld for taxes (in shares)         202,000 1,040,000                
Stock units vested, net of shares withheld for taxes (3,975)   $ 0   $ 2 $ 10     $ (3,977) $ (10)        
Exchange of 2024 notes (in shares)       1,294,000                    
Exchange of 2024 notes 23,073     $ 13     23,060              
Shares issued for acquisition (in shares)       8,475,000                    
Shares issued for acquisition 261,271     $ 85     261,186              
Class A common stock issued for payment of earn-outs (in shares)       877,000                    
Class A common stock issued for payment of earn-outs 28,551     $ 9     28,542              
Foreign currency translation adjustment (79)                   (79)      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (142,260)           (29,220)         (113,040)    
Ending balance (in shares) at Dec. 31, 2023 115,424,833     115,425,000                    
Ending balance at Dec. 31, 2023 $ 1,067,701     $ 1,154     1,808,121       (1,257) (719,194)   (21,123)
Series A preferred stock , ending balance (in shares) at Dec. 31, 2024 175,000                          
Series A preferred stock , ending balance at Dec. 31, 2024 $ 190,173                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation expense $ 39,746           39,746              
Exercise of stock options (in shares) 283,000     335,000                    
Exercise of stock options $ 3,461     $ 4     3,457              
Restricted stock units vested, net of shares withheld for taxes (in shares)       611,000                    
Restricted stock units vested, net of shares withheld for taxes (11,135)     $ 6     (11,141)              
Stock units vested, net of shares withheld for taxes (in shares)         205,000                  
Stock units vested, net of shares withheld for taxes (4,564)       $ 2       $ (4,566)          
Foreign currency translation adjustment (496)                   (496)      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (93,454)           (31,831)         (61,623)    
Ending balance (in shares) at Dec. 31, 2024 116,575,773     116,576,000                    
Ending balance at Dec. 31, 2024 $ 1,001,259     $ 1,166     $ 1,803,786       $ (1,753) $ (780,817)   $ (21,123)